Categories
Archives
Receive Email Updates
-
-
-
Certified Licensing Professionals, Inc., 2021 
Disclaimer
This blog, Patents4Life, does not contain legal advice and is for informational purposes only. Its publication does not create an attorney-client relationship nor is it a solicitation for business. This is the personal blog of Warren Woessner and does not reflect the views of Schwegman Lundberg & Woessner, or any of its attorneys or staff. To the best of his ability, the Author provides current and accurate information at the time of each post, however, readers should check for current information and accuracy.
-
- About Me
Warren D. Woessner
Pages
Archives
Tag Archives: biotechnology
The Unacknowledged Role of Section 112 in the Myriad Decisions
Guest post from Paul Cole, Lucas & Co., UK; introduction by Warren Woessner. In this interesting note, Paul Cole explores the possible effect on the Fed. Cir. and Supreme Court’s decisions about the patent-eligibility of “genomic DNA” of the arguable … Continue reading
Posted in Patent Eligible Subject Matter
Tagged application to bacterial genes, biotechnology, biotechnology law, blanket prohibition, BRCA1, cDNA, chemist or geneticist, Enablement, evaluation, full-length gene partial sequence, intellectual property, ip, Myriad, Patent Law, patent-eligibility, patents, Paul Cole, structural difference threshold, utility threshold, Warren Woessner, written description
Leave a comment
Sanofi-Aventis v. Pfizer – Possession and Appreciation Trump Structure
On Tuesday, the Fed. Cir. affirmed a finding by the Board that Pfizer was entitled to an earlier priority date for a claim to cDNA encoding the IL-13 receptor protein (Sanofi-Aventis v. Pfizer, Inc., App. No. 2012-1345 (Fed. Cir. November … Continue reading
Novozymes Loses “Possession” Of Its Enzyme
I am not sure how I missed this decision, which came down on July 22nd, but it offers a rather scary hi-def picture as to where the written description requirement of s. 112 has been and where it is headed. … Continue reading
Supreme Court Will Not Review Therasense Standards – Yet
On October 15, 2013, after reviewing the Government’s Amicus Brief (a copy is available at the end of this post), the Supreme Court denied the petition for cert. filed by Sony Computer Entertainment, one of the defendants in 1st Media, … Continue reading